CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- Open-market buys, last 90 days
- $22,023,904
- in 7 filings
- Open-market sales, last 90 days
- $4,490,340
- in 8 filings, $4.5M under 10b5-1 plans
Net +$17,533,565. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-13 | Ignelzi Troy A. Chief Financial Officer | Purchase | +100 | $9.98 | $998 | 10,000 |
| 2025-03-12 | Ignelzi Troy A. Chief Financial Officer | Purchase | +9,900 | $10.10 | $100K | 9,900 |
| 2025-03-12 | Young Wendy B. Director | Purchase | +6,000 | $10.21 | $61K | 6,000 |
| 2025-03-03 | Gault Cheryl Chief Operating Officer | Grant or award | +13,987 | 171,928 | ||
| 2025-02-03 | Ignelzi Troy A. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +142,000 | 142,000 | ||
| 2025-02-03 | Yeleswaram Krishnaswamy Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2025-02-03 | Bredt David Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-02-03 | Ceesay Abraham Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +428,000 | 428,000 | ||
| 2025-02-03 | Gault Cheryl Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +129,000 | 129,000 | ||
| 2024-11-07 | Young Wendy B. Director | Grant or award · Stock Option (Right to Buy) | +29,756 | 29,756 | ||
| 2024-11-07 | PEREZ ROBERT J Director | Grant or award · Stock Option (Right to Buy) | +29,756 | 29,756 | ||
| 2024-11-07 | Silva Paul M Director | Grant or award · Stock Option (Right to Buy) | +29,756 | 29,756 | ||
| 2024-11-07 | Sanchez Ramiro Director | Grant or award · Stock Option (Right to Buy) | +29,756 | 29,756 | ||
| 2024-07-01 | HEALY JAMES Director | Purchase | +3,538 | $23.08 | $82K | 28,993 |
| 2024-07-01 | HEALY JAMES Director | Purchase | +3,565 | $24.21 | $86K | 32,558 |
| 2024-07-01 | HEALY JAMES Director | Purchase | +4,544 | $25.02 | $114K | 37,102 |
| 2024-07-01 | HEALY JAMES Director | Purchase | +2,559 | $26.06 | $67K | 39,661 |
| 2024-07-01 | HEALY JAMES Director | Purchase | +3,799 | $23.08 | $88K | 21,660 |
| 2024-07-01 | HEALY JAMES Director | Purchase | +3,828 | $24.21 | $93K | 25,488 |
| 2024-07-01 | HEALY JAMES Director | Purchase | +4,878 | $25.02 | $122K | 30,366 |
Page 8 of 10 · 186 trades